Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + capecitabine with preoperative radiotherapy for locally advanced rectal cancer
2005-000802-30Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and capecitabine in rectal cancer, sponsored by Roche. Primary endpoints: Pathological complete response by local pathologist, Pathological tumor assessment by central pathologist and 2 more. Started Dec 2008; status: completed.
02
Drugs
bevacizumabcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2005-000802-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000802-30.